Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
Circadence Corp., a Boulder-headquartered cybersecurity firm, recently closed a $16.4 million investment round.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results